Mansoor Mirza

Chief Oncologist

Rigshospitalet

Denmark

Research Interests

Explore related searches

Professors in Cancer Biology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mansoor Mirza serves as the Chief Oncologist at Rigshospitalet in Denmark. His research focuses on various aspects of gynecological oncology, with recent contributions addressing chemotherapy management in endometrial and ovarian cancer, as well as the potential effects of various medications on patient survival. His work also explores innovative testing methods and treatment combinations to enhance patient outcomes in ovarian cancer.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (9)

Karin Piil

Copenhagen University Hospital

DENMARK

View details

isabelle ray coquard

professor

FRANCE

View details

Jonathan Ledermann

University College London

UNITED KINGDOM

View details

Susana Banerjee

Reader in Women's Cancers (Systemic Therapy and Clinical Trials)

Institute of Cancer Research

UNITED KINGDOM

View details

Frederik Otzen Bagger

Head of Bioinformatics

Rigshospitalet

DENMARK

View details

Sarah (Sally) J Lord

Associate Professor, Research

The University of Notre Dame Australia

AUSTRALIA

View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA

View details

Antonio González-Martín

SPAIN

View details

Robert L. Coleman

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mansoor Mirza

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Systematic nurse-led consultations based on electronic patient-reported outcomes for women with endometrial or ovarian cancer during chemotherapy—a feasibility study

Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023

Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity

Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context

SystematiC nurse-led cONsultations based oN Electronic patient-reported outcome among women with ovarian- or endometrial Cancer during chemoTherapy – protocol for the CONNECT study

Collaborators (9)

Karin Piil

isabelle ray coquard

Jonathan Ledermann

Susana Banerjee

Frederik Otzen Bagger

Sarah (Sally) J Lord

Clare Scott

Antonio González-Martín

Robert L. Coleman

Make your next move.